Full-Time
Confirmed live in the last 24 hours
Develops gene editing technology for genetic medicine
Expert
Cambridge, MA, USA
You match the following Tessera Therapeutics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company primarily serves research institutions, pharmaceutical companies, and healthcare providers seeking to develop new treatments for genetic diseases. Unlike its competitors, Tessera emphasizes the versatility of its technology and its potential to address previously untreatable conditions. The goal of Tessera Therapeutics is to advance genetic medicine by rewriting the genetic code to cure diseases.
Company Size
201-500
Company Stage
Series C
Total Funding
$518.2M
Headquarters
Cambridge, Massachusetts
Founded
2018
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Tuition Reimbursement
Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company's in vivo programme for sickle cell disease (SCD).
Tessera is developing Gene Writers(TM) for SCD designed to enable a true correction of the sickle mutation to wild-type with one-time intravenous administration in vivo, without the need for complex stem cell mobilization or toxic chemotherapy conditioning.
Tessera Therapeutics receives investment to develop curative in vivo genetic treatment for sickle cell disease.
The Bill & Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support its development of in-vivo genetic medicines for sickle cell disease. Tessera aims to offer a one-time intravenous treatment that avoids the need for high-dose chemotherapy and complex stem cell mobilization, unlike existing ex-vivo therapies. Tessera, founded by Flagship Pioneering, previously raised $230 million in Series B financing in 2021 and $300 million in 2022.
Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing
The chief executive officer of Tessera Therapeutics discussed ongoing research into developing its platform for sickle cell disease, CAR T-cell therapy, and more.
SAN JOSE, Calif.--(BUSINESS WIRE)--Xperi Inc. (NYSE: XPER) (the “Company” or “Xperi”), an entertainment technology company that invents, develops and delivers technologies that enable extraordinary experiences, today publicized a letter written by one of its directors who is not being targeted by activist stockholder Rubric Capital, Christopher Seams. Mr. Seams served on the board of one of Xperi’s predecessors while one of Rubric’s nominees, Thomas Lacey, was CEO of that predecessor company. In the letter, Mr. Seams expresses his support for the targeted directors, highlights their contributions to Xperi’s multi-year transformation and contrasts their expertise in software development, technology, audio-visual technologies and content monetization with Rubric’s nominees’ lack of experience in these critical areas
The Boston region in the U.S. state of Massachusetts (MA) hosts one of the leading biotech hubs in the world, ranking second just in front of the BioHealth Capital Region. Here are twelve of Boston’s most innovative biotech companies.The Boston region has sprouted many influential public biotech companies. One of the most successful in recent years was Moderna, a giant messenger RNA (mRNA) specialist incubated by the VC firm Flagship Pioneering. Moderna would go on to produce one of the first COVID-19 vaccines in 2020. Another prestigious name, Vertex Pharmaceuticals, one of the 14 biotechs with a market capitalization above $100 billion, is also headquartered in Boston.The Boston hub shows few signs of slowing down, and there is a host of biotech companies generating excitement among investors.Table of contentsAkouosAkouos, founded in 2016 focuses on developing gene therapies for hearing loss
Arthrosi Therapeutics, a biotech company developing a gout treatment, raised a fresh $75 million through a Series D round.
RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency (AATD) and sickle cell disease (SCD) including proof of concept in non-human primates (NHPs) for PKU. RNA Gene Writing™ technology enables multiplexed full-length gene writing and rewriting with RNA-only delivery to engineer CAR-T cells with robust antitumor activity. Proprietary lipid nanoparticle (LNP) delivery demonstrates potential to effectively reach cell types beyond hepatocytes including hematopoietic stem cells (HSCs) and T cells